View in EDS

LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours.

Saved in:
Bibliographic Details
Title: LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours.
Authors: Lwin, Z.1 (AUTHOR), Gomez-Roca, C.2 (AUTHOR), Saada-Bouzid, E.3 (AUTHOR), Yanez, E.4 (AUTHOR), Muñoz, F. Longo5 (AUTHOR), Im, S-A.6 (AUTHOR), Castanon, E.7 (AUTHOR), Senellart, H.8 (AUTHOR), Graham, D.9 (AUTHOR), Voss, M.10 (AUTHOR), Doherty, M.11 (AUTHOR), Lopez, J.12 (AUTHOR), Ghori, R.13 (AUTHOR), Kubiak, P.14 (AUTHOR), Jin, F.15 (AUTHOR), Norwood, K.15 (AUTHOR), Chung, H.C.16 (AUTHOR)
Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS1170-S1170. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2020.08.2271